Expand CLRB Menu
CLRB MENU

CLRB Latest Press Releases

-- February 17, 2026 --

Cellectar Biosciences Expands Global Intellectual Property Estate Globe Newswire 8:05 AM

-- January 9, 2026 --

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference Globe Newswire 8:05 AM

-- December 16, 2025 --

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies Globe Newswire 8:05 AM

-- November 13, 2025 --

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 7:20 AM

-- November 6, 2025 --

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 Globe Newswire 8:05 AM

-- October 27, 2025 --

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma Globe Newswire 8:30 AM

-- October 14, 2025 --

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research Globe Newswire 8:30 AM

-- October 7, 2025 --

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million Globe Newswire 8:30 AM

-- October 6, 2025 --

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Globe Newswire 7:00 AM

-- September 30, 2025 --

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Globe Newswire 8:30 AM

-- September 24, 2025 --

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes